Subgroup analyses based on baseline BMI categories showed inconsistent trends in the semaglutide arm: weight loss during treatment (week 0 to week 68) showed no clear trend across increasing BMI categories, but over week 0 to week 120 showed a trend for greater weight loss in the subgroups of patients with higher versus lower baseline BMI categories, in part owing to a lesser weight regain in the 40 kg/m 2 or higher subgroup than most others.
← all excerpts
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
1
—
—